Literature DB >> 11236926

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

R Murata1, J Overgaard, M R Horsman.   

Abstract

PURPOSE: To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to change tissue blood perfusion.
MATERIALS AND METHODS: The tissues were a C3H mouse mammary carcinoma and various murine normal tissues, with perfusion measured using the 86RbCl extraction technique.
RESULTS: CA4DP (250mg/kg; i.p.) reduced tumour perfusion to 34% of that seen in controls within 1 h of injection. It was maintained at this for at least 6 h, returning to control levels by 24 h. This decrease was dose-dependent. DMXAA (25mg/kg; i.p.) caused a 79% reduction in tumour perfusion 6h after injection; no recovery was observed even after 24 h. DMXAA showed no changes at doses below 10 mg/kg. Both CA4DP and DMXAA increased perfusion in the gut, kidney, bladder and lung, while decreasing splenic perfusion. CA4DP tended to decrease perfusion in muscle, while DMXAA increased liver perfusion. These changes in normal tissue perfusion were generally less than those changes seen in tumours. No significant changes were seen in skin.
CONCLUSIONS: CA4DP and DMXAA produced a selective and significant reduction in tumour perfusion, but the pattern of change was different. These results suggest how these vascular targeting drugs should be combined with more conventional therapies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236926     DOI: 10.1080/09553000010007695

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  17 in total

1.  TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

Authors:  Abigail F Welford; Daniela Biziato; Seth B Coffelt; Silvia Nucera; Matthew Fisher; Ferdinando Pucci; Clelia Di Serio; Luigi Naldini; Michele De Palma; Gillian M Tozer; Claire E Lewis
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

2.  Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.

Authors:  Lotte B Bertelsen; Yuan Yuan Shen; Thomas Nielsen; Hans Stødkilde-Jørgensen; G Kenneth Lloyd; Dietmar W Siemann; Michael R Horsman
Journal:  Int J Radiat Biol       Date:  2011-11       Impact factor: 2.694

Review 3.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

4.  Cholesterol superlattice modulates CA4P release from liposomes and CA4P cytotoxicity on mammary cancer cells.

Authors:  Berenice Venegas; Weiwei Zhu; Nicole B Haloupek; Janet Lee; Elizabeth Zellhart; István P Sugár; Mohammad F Kiani; Parkson Lee-Gau Chong
Journal:  Biophys J       Date:  2012-05-02       Impact factor: 4.033

5.  Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.

Authors:  Michael Kragh; Bjørn Quistorff; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

6.  Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors.

Authors:  Christopher B Pattillo; Berenice Venegas; Fred J Donelson; Luis Del Valle; Linda C Knight; Parkson L-G Chong; Mohammad F Kiani
Journal:  Pharm Res       Date:  2009-01-27       Impact factor: 4.200

7.  Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.

Authors:  Patricia M LoRusso; Shirish M Gadgeel; Antoinette Wozniak; Alan J Barge; Helen K Jones; Zachary S DelProposto; Pamela A DeLuca; Jeffrey L Evelhoch; Scott A Boerner; Catherine Wheeler
Journal:  Invest New Drugs       Date:  2008-01-25       Impact factor: 3.850

Review 8.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

9.  Volumetric Arterial Spin-labeled Perfusion Imaging of the Kidneys with a Three-dimensional Fast Spin Echo Acquisition.

Authors:  Philip M Robson; Ananth J Madhuranthakam; Martin P Smith; Maryellen R M Sun; Weiying Dai; Neil M Rofsky; Ivan Pedrosa; David C Alsop
Journal:  Acad Radiol       Date:  2015-10-29       Impact factor: 3.173

10.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.